Canary Pharma Limited - pharma in Indore, Madhya Pradesh, India. Directors, charges & compliance details.
CIN U24232MP1995PLC008940 Incorporated 17 January 1995 ROC Gwalior HQ Indore, Madhya Pradesh, India
Converted to LLP Public Limited Company pharma
Revenue · FY 2023
₹4,850
▼ 15% YoY
Authorised capital
₹18 Lakh
Registered with MCA
Paid-up capital
₹18 Lakh
Issued & subscribed
Company age
31 yrs
Est. 1995
Directors on board
3
As per MCA filings
Last financials
Mar 2023
Balance sheet date
Last AGM
15 Jun 2023
Annual general meeting
Company status
Converted to LLP
MCA master data

About Canary Pharma Limited

Data last updated:

Canary Pharma Limited was a public limited company based in Indore, Madhya Pradesh, India. The company has been converted to a Limited Liability Partnership (LLP) and no longer exists as a company. For the latest details, refer to the successor LLP. It operated in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 January 1995.

The company was registered with the Registrar of Companies (ROC), Gwalior, under CIN U24232MP1995PLC008940.

The company had an authorised share capital of ₹18 Lakh and a paid-up capital of ₹18 Lakh. It was led by directors including Kiran Deshmukh and Ankit Mehta.

Its last annual general meeting (AGM) was held on 15 June 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office was at 12 Rajgadh Kothi Manoramaganj Behind United Tyres, Indore, Madhya Pradesh, India – 452001.

Company details

CIN U24232MP1995PLC008940
Registration Number 008940
Incorporation Date 17 January 1995
ROC Gwalior
Listing Status Unlisted
Company Status Converted to LLP
Compliance Status Active Compliant

Contact details

Canary Pharma Limited's registered office is in Indore, Madhya Pradesh. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    12 Rajgadh Kothi Manoramaganj Behind United Tyres, Indore, Madhya Pradesh, India – 452001
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Canary Pharma Limited, buy the company report.

Comprehensive company report
Canary Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Canary Pharma is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Canary Pharma Limited, buy the company report.

Financials of Canary Pharma Limited

FY 2023 filings available

Canary Pharma Limited reported revenue of ₹4,850 (down 15% YoY) for FY 2023.

Revenue · FY 2023
₹4,850 ▼ 15%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 15%
3 years · compounded
▼ 50%

Revenue has declined at a compounded annual rate (CAGR) of 50% over three years, including a 15% fall in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA
Profit Before Tax
Tax Expense
Net Profit (PAT)
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profitability
EBITDA Margin
Net Profit Margin
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Canary Pharma Limited, buy the company report.

Board of directors of Canary Pharma Limited

Canary Pharma has 3 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.

Directors (as last reported)
NameDesignationAppointment DateTenureStatus
Kiran DeshmukhDirector21 Jun 200620 Years 4 MonthsAs last reported
Ankit MehtaDirector12 Mar 201214 Years 8 MonthsAs last reported
Prateek DeshmukhDirector01 Mar 20197 Years 8 MonthsAs last reported

Auditor

Canary Pharma Limited is audited by BHORKAR & KULKARNI for the financial year 2017.

Auditor firmFinancial yearFirm registration number
BHORKAR & KULKARNIFY 2017006696C

Shareholding

The shareholding of Canary Pharma Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2017FY 2016
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Canary Pharma Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Canary Pharma Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

No GST registration is on our record for Canary Pharma Limited; the GSTIN and return-filing check is in the company report Buy the company report.

Recent activity

Canary Pharma Limited has 8 board changes on record since 2006: 3 appointments and 5 cessations. The latest: Sanjay Mirikar ceased to be Director on 05 Mar 2019.

AGM
Canary Pharma Limited last Annual general meeting of members was held on 15 Jun 2023 as per latest MCA records.
Filing
Canary Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Gwalior.
Ceased
Sanjay Mirikar ceased to be Director.
Appointed
Prateek Deshmukh was appointed as Director.
Ceased
Ankit Mehta ceased to be Additional Director.
Ceased
Neena Bhatjiwale ceased to be Director.
Ceased
Raghav Bhatjiwale ceased to be Director.
Ceased
Sanjeev Bhatjiwale ceased to be Director.
Appointed
Ankit Mehta was appointed as Director.
Appointed
Kiran Deshmukh was appointed as Director.
Incorporation
17 Jan 1995
Canary Pharma Limited was registered on 17 Jan 1995 with Roc Gwalior & aged 31 years 10 months as per MCA records.

Frequently asked questions

Canary Pharma has been "Converted to LLP" - the business changed its legal structure from a company to a Limited Liability Partnership. The original company no longer exists in its previous form. For the latest information, refer to the successor LLP entity registered with MCA.

Canary Pharma was a public limited company based in Indore, Madhya Pradesh, India. The company worked in drug formulation and development, within the pharma industry. It was incorporated on 17 January 1995 and is registered under CIN U24232MP1995PLC008940. For the latest details, refer to the successor LLP entity.

The CIN (Corporate Identification Number) of Canary Pharma is U24232MP1995PLC008940. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Canary Pharma had 3 directors:

Canary Pharma was incorporated on 17 January 1995. It is registered with the Registrar of Companies, Gwalior.

The registered office of Canary Pharma is at 12 Rajgadh Kothi Manoramaganj Behind United Tyres, Indore, Madhya Pradesh, India – 452001.

The latest financial statements of Canary Pharma on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 15 June 2023. Year-wise statements from 2015 are in the company report.

Canary Pharma operated in the pharma industry, in the drug formulation and development segment.

Sanjay Mirikar ceased to be Director on 05 Mar 2019. Prateek Deshmukh was appointed as Director on 01 Mar 2019. Ankit Mehta ceased to be Additional Director on 29 Sep 2012. Canary Pharma has 8 board changes on record in total.

The compliance status of Canary Pharma is compliant as of 28 July 2026.